PMEF
PLRX icon

Point72 Middle East FZE’s Pliant Therapeutics PLRX Stock Holding History

Point72 Middle East FZE’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-758
Closed -$13.7K – 1780
2023
Q2 		$13.7K Sell
758
-7,025
-90% -$166K ﹤0.01% 1400
2023
Q1 		$207K Buy
+7,783
New +$222K 0.01% 940

Other funds holding PLRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Point72 Middle East FZE's PLRX Position: Q3 2023 in Review

Point72 Middle East FZE sold out of Pliant Therapeutics (PLRX) in Q3 2023, closing a stake of 758 shares — an estimated $13.7K sold.

Point72 Middle East FZE first reported a position in PLRX in Q1 2023 and held it in 2 quarters. The position peaked at $207K in Q1 2023. 136 funds tracked by Wall St. Rank hold PLRX as of Q3 2023.

  • Point72 Middle East FZE reported no remaining Pliant Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 758 Pliant Therapeutics shares in Q3 2023, an estimated $13.7K.
  • Point72 Middle East FZE first reported a position in Pliant Therapeutics in Q1 2023 and held it in 2 quarters.
  • Point72 Middle East FZE's Pliant Therapeutics position peaked at $207K in Q1 2023.
  • 136 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2023.

Based on Point72 Middle East FZE's 13F filing for Q3 2023, filed 14 Nov 2023.